exercise ; cardiovascular system

cox proportional hazards models
case-control study
EH
practices


Clinical
HF

reporting ; Cell ; Anand
doxorubicin ; injected
doctors ; blood transfusions
FM
adverse events
devices ; heart failure
dXA
Liver disease ; adults

HF ; pna
exercise ; cardiovascular health
Renal artery stenosis

surgery ; heart transplant recipients
inhospital mortality
molecular mechanism
tertiary referral centre
NO production ; EC
HF


trial
mortality
Periodic breathing ; heart beat

Retrospective co
heart failure ; Latin America

Trials
Heart rate

doctors ; die
nutrition ; heart failure
Northwest United states

unilateral
surgery
heart failure
INTERventions

Heart failure ; young

clin
Sci
trans

CHF treatments
autonomic balance
competitive ; collateral growth
intermediate frailty
HFpEF
ST2

dodson ; interest

LV fibrosis ; ANS mice

Jehovah ; Witness ; severe anemia
medical conditions
hospital ; heart failure
cardiac transplantation
Indices ; co
impact of frailty ; HF
cognitive function
Heart failure ; cognitive impairment ; mortality
HF ; HF cases
follow-up duration
cardiology ; university hospital
exercise modality
Heart rate variability ; cardiac patients
remote ischemic conditioning ; patients ; heart failure
air pollution ; heart failure

Sham-operated animals


policy recommendations
compliance ; treatment

taxonomy
CHF
Heart failure ; UK

cardiovascular disease
HF ; MI
extracorporeal
Heart failure ; disease
markers of hemostasis

Caspase-3 gene expression ; heart failure
diuretic ; heart failure
right heart failure ; pulmonary hypertension
Heart failure ; bisphosphonates

MR ; MS
patients ; hypertension
american ; european HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure patients
genes
internal reliability ; cronbach
HFpEF
ejection fraction ; bNP
Pigs ; antiarrhythmic medication
therapy ; beta blockade
CHF patients ; intubated
Surgical tactics ; brief hypothermic circulatory arrest


systolic dysfunction
Literature
trial
exercise ; heart failure
implanted monitoring devices
Few treatments
patient safety ; conditions
HR ; Ea ; afterload burden
periprocedural ; strokes
median age
RAS ; atherosclerosis
frailty ; heart failure
MicroRNAs ; heart failure ; disease management
Hazard ratios ; cox regression
PSSS ; exercise training
management of heart failure ; preserved ejection fraction
Cardiology ; Bromodomain inhibition halts heart failure
AT
vasopressin ; congestive heart failure
Mitral stenosis reversed ; medical treatment ; heart failure
heart failure hospitalization ; cardiovascular death
Trastuzumab-related cardiotoxicity ; breast cancer
devices ; cornerstone of heart failure ;HF ; therapy
sts HM
pde2 ; HF
Nights ; hospital
Heart failure ; public health
postoperative normalization ; albumin level
VET ; aortic pressure curve
physician continuity ; discharge
Medication regimen ; sst2

Cardiac symptoms ; congenital lesions
spironolactone ; systolic heart failure
eRK1/2 molecular scaffolds ; heart pathology
functional MS ; degenerative MR
Epidemiology ; chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox proportional hazards models
physician volume ; hospital
Tolvaptan ; vasopressin ; receptor antagonist
arrhythmia-related costs ; expenditures
metric ; readmission metrics
readmission ;metric

median


black patients
mechanism ; ET exerts ; CHF
HF
residual confounding ; follow-up
life ; well-being
propensity
hgb level ; baseline ; HRQoL
ejection fraction ; trial
biomarkers ; chronic heart failure
HF ; cardiovascular hospitalization
cardiac ; inflammatory biomarkers
mortality
heart failure ; emergency department
Pharmacological ; acute heart failure
baseline ; heart failure
off-pump ; sternal sparing ; HeartMate II exchange
dialysis ; device implantation
Coronary angiography
Hemodynamic ; failing Fontan
MS ; surgery ; echocardiography

factors ; survival
heart failure ; cox proportional hazard
Nordic walking ; heart failure
psychometric testing ; self-Care of Heart Failure index
postoperatively ; multiorgan failure ; sepsis
acute kidney injury
VO2max
cox proportional hazards models
Survival projections ; Seattle Heart Failure model
healthcare programmes
heart failure


trials
abnormal cardiac t2 ; treatment
clinical trials

HR ; HF
prognostic factors
drug ; Japan
biomarkers
figure ; TUg test
ESRD
Heart failure ; preserved left ventricular ejection fraction

systolic HF

lVAD implantation
postystolic function
medication ; resting hemodynamics
prognosis ; pathophysiological
mice ; aac ; cardiac hypertrophy
AHA ; AHA ; ESC
physical ; heart failure
skeletal muscle abnormalities ; exercise capacity ; Fontan circulation
Readmission ; hospital ; heart failure ; discharge
progressive disease ; hypertension ; end stage kidney failure
chronic kidney disease ;CKd
income ; expenditure ; health per capita
longitudinal change
abnormal HR variability ; sudden ; non-sudden cardiac death
circulation
toxicity ; systemic blood pressure


therapy
enrollment
adherence ; cPGs
MS

acute heart failure trials
patients ; heart failure
diagnostic devices ; HF
end stage heart failure
HF
endothelial function ; flow-mediated dilatation
Race ; spironolactone ; severe heart failure
heart failure ; cardiac rehabilitation
Rhythm- and rate-control strategies
race ; exercise training
anemia ; heart disease
physicians ; HF
Myocardial infarction ; Wistar rats
Treatment algorithms ; post-LVAD AI
AI ; surgical
sinus rhythm ; AF
public reporting ; quality ; hospitals
preoperative demographics
care management ; telehealth ; medicare
ec ;septal ; filling pressures

HF ; chromatin hyperacetylation
nursing terminologies
acute heart failure

ms ; surgery
gls ; cv events ; AF
deficit index ; deficits


mortality
hospitals
QRs duration

CHF ; unilateral renal DNx ; cardiac autonomic balance
Mitral regurgitation ; HF
renin-angiotensin-aldosterone system inhibitors ; heart failure
anaerobic threshold ; heart failure
MS
af pacientes ; echocardiographic examination
Nurses ; patients ; managing
economic savings ; cost
PVf ; recovery ; PB
care packages ; health
congenital heart lesions
MS ;HF ; surgical indication ; MS
ICU mortality
Bioinformatic ; microarray ; heart failure
cardiovascular events ; deaths
diuretic ; HF
CAD ; systolic HF
resistin ; inflammation ; metabolism ; heart disease
sst2 ; BB therapy
Heart block ; pulmonary artery snared ; biVP
compliance
cRT ; dialysis-dependent patients
beta-blockers
CHF
care ; RM
HF
Cardiac function ; pressure-volume conductance ; catheter system
idiopathic dilated cardiomyopathy
unfolded protein response ; cardiac sodium current ; systolic human heart failure
Hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; MS
cd HF ; etiologies
angiotensin receptor neprilysin inhibitor ; heart failure
western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
ischemic cardiomyopathy ; male sex ; mortality
AF ; precipitating factor ; clinical deterioration ; hFPEF
heart transplant ; ECCT
proteome ; HDl particles ; shotgun ;LC-MS
Frailty ; risk ; HF
southeastern Minnesota ; HF
bundle ; branch block electrical activation sequence
hHF ; dp-4 inhibitors ; drugs
proteins ; TAC
Cardiac cachexia ;cc ; body composition
signalling pathways ; maladaptive cardiac remodelling
dialysis
safety ; neurological ; cardiovascular
coronary disease ; heart failure
ff ; FM ; body weight ; CC
multihospital ; heart failure ; nurse leaders
exercise training ;ET ; endothelial function
MS
social support ; exercise ; exercise
heart rate variation
cRF
Mediterranean ; DASh
length ; rehospitalization
nitroxyl ; hno ; acute treatment ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ratios ; accounting ; hospital
change ; lVET ; follow-up measurement
blacks ; baseline
physician continuity ; death ; urgent readmission ; discharge ; patients ; heart failure
hFref ; HFpEF ; regression line
hospital ; readmission reduction program ; congestive heart failure
death ; hospitalization ; heart failure clinic outpatients
diabetes ; EO-CFUs
patient safety
transplants
aerobic exercise
outcome performance
trastuzumab-related CHF
hospitals
Peak VO2
procedures ; pharmaceutically
financials
Coronary artery disease ;CAD ; systolic heart failure ;HF
preoperative hypoalbuminemia ; lVAD surgery
psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam
mortality ; HF hospital admissions ; transplant ; ventricular assist device
Heart failure risk ; rheumatoid arthritis ; tNF antagonist
holosystolic murmur ; third heart sound
CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
HF ; haemodynamic ; neuronal stressors
deficit index ; biological ; mortality
right ventricular function ; body composition ; advanced heart failure
Fat ; cachexia ; right ventricle ; heart failure
atrial fibrillation ;AF ; heart failure
ecCT ; advanced heart failure therapy
eligibility ; heart transplantation ; left ventricular assist device
exercise intolerance ; chronic heart failure
AVd ; VVD ; free wall RS
clinical ; resistin levels ; heart failure
baseline eCGs ; electrocardiographers
Survival ; left ventricular assist device ; right ventricular support
incidence ; ESRD ; outpatients ; HF
Wilcoxon ; signed-rank tests
subclinical atherosclerosis ; general linear models
Renal artery stenosis ;RAS ; peripheral arterial disease
ecCT ; cardiac transplant recipients
eplerenone ; primary composite endpoint
recovery
extubated ; blood loss ; transfusion
exchange malfunctioning HeartMate II lVADs
Heart failure ;HF ; cardiovascular hospitalization
veGF inhibition ; b ; cardiac function ; remodeling
β-blocker ;BB ; sst2
miRNAs ; cardiac pathogenesis
cPET guiding exercise rehabilitation ; CHF
heart failure ; ejection fraction
heart failure ; medication
Pediatric heart failure ;HF ; morbidity ; mortality
regulatory ;RI ; HF
discharge ; follow-up medication
bromodomain proteins
preoperative ; mortality
heart failure ; readmission
bt ; DT
Fatal ; nonfatal outcomes ; hospitalization rates
hypotension
biomarkers ; HF
incident HF
ST2 ; plasma samples
economic
prescribing guideline-recommended medications ; heart failure
mortality rate
coronary heart disease ; stroke ; heart failure
quality of life ;MLHF
septal defects ; surgical
mortality ; iCD-HF
Unilateral renal denervation ; autonomic balance ; rabbits ; chronic heart failure

trastuzumab
pre-HCT germline DNA ; genotyped
Heart failure disease ; medical resource ; survival
Renal DNx ; circulating plasma NE ; CHF-inv rabbits
HF
blood work drawn ; medication
NP assessment ; ED
Cardiac hypertrophy ; energy metabolism
lVAD implantation
HDl-bound malondialdehyde ; HDl-induced NO production ; ec
Age ; renal dysfunction ; post-transplant morbidity
derivation cohort ; CAD ; severe CAD


Survival ; hospital discharge
hospitals
anemia ; heart disease
right atrial myxoma ; pulmonary embolism ; right heart failure
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
resistin correlated ; decline ; ejection fraction
Orthotopic heart transplantation ; oHT ; end-stage heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
readmissions ; follow-up visits ; heart failure ; readmission quality
lVAS ; bridge to transplantation ; destination therapy
Cardiac ; Mammalian ;Mena ; heart failure ; mice
cps ; functional capacity ; peak VO2
pump failure ; driveline injury ; isolated pump replacement
apoptosis ; canine model ; chronic heart failure induced ; tachycardia
Nicorandil ; doxorubicin
EH ; HFpEF
east ; rhythm control therapy ; cardiovascular complications ; AF
radiological ; HF
diuretics ; congestive symptoms ; heart failure ;HF
evidence-based therapies
s2 ; heart failure
Framingham Heart study criteria ; HF ; EF
HF
aCR ; CMS
band of activated Caspase ; paced myocardium
Frailty ; risk ; heart failure ; aging ; body composition
hf ; saxagliptin ; sitagliptin
Heart t2 ; heart failure ; arrhythmias
ischemic ; inflammatory abdominal ; MT group
ED ; intubations ; congestive heart failure
Medline ; EMBAse ; cinahl
evidence ; aCP ; clinical practice guidelines
exercise ; adverse events ; coronary artery disease ;CAD

clinical change
ED ; CHF
QRs
Medicare ; post-acute care transfer policy
Diet score ; vegetables ; nuts ; whole grain intake ; mortality

degs ; osprey
therapy
electronic databases ; world health organization ; HF
deficit index
device implantation ; cRT

iron
remote monitoring ; hospital discharge ; patients ; heart failure
LV ; filling pressure ; severe systolic HF
Soluble ST2 ; ambulatory patients ; heart failure
baseline ; echocardiograms
Titin hypophosphorylation ; myocardial DD
right ventricular contractile reserve ; pulmonary hypertension
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
RAS- ; β-blocker uptitration ; HFpEF
compliance ; exercise ; injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
NOc ; admission ; discharge
HRQoL ; exercise training ; baseline hgb
inpatient records ; HF
skeletal muscle mass correlated ; poorer VO2
emergency cardiac catheterization ; extubated ; intermediate
psychosocial factors ; exercise training ; heart failure ;HF
medical management ; heart failure ; Canadian Cardiovascular society
active treatment ; placebo
laboratory report model ; aRIC HF model
atrial fibrillation ; pacemaker
mortality predictors ; iCD-HF
patients ; cardiovascular
AF-free probability ; catheter ablation ; factors ; maintenance ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
human myocardial tissue ; pKA
paediatric cardiac transplants ; children
ees ; ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic restriction to flow
autonomic nervous system activity ; QTV
pneumonia ; surgical conditions
t1 mapping ; myocardial fibrosis

high-risk patients
exercise ; diet adherence
white
ethics Rounds

Biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; pathophysiology ; medical Treatment guidelines ; Nursing management
anemia ; heart disease ; clinical practice guideline ; American college of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
end-stage renal disease ; outpatients ; systolic heart failure
rvpo ; biVP ; co ; RS synchrony ; CS
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; acute anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; QTV ; HF
Heart rate ; aortic blood flow ; doxorubicin
hospitalisations ; readmissions ; mortality
myocardial pde2 expression ; activity ; HF
BAT ; sympathetic outflow ; parasympathetic activity
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ; HF hospitalization ; exercise training ; btes
exercise training ; chronic heart failure ; high-density lipoprotein
Neurohormonal abnormalities ; congestive heart failure ;CHf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVEF ; long-term mortality
Mediterranean ; DASh ; mortality ; heart failure ; women ; health Initiative
Jehovah's Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide ; oxygen flow
health Buddy program ; ED
l-type ca2 ; currents ; Rad ; congestive heart failure
cps ; outcomes ; diabetes
resistin levels ; anthracycline-treated breast cancer ; cardiotoxicity
pulmonary artery ; right pulmonary artery
Animals ; mRI scanner ; baseline ; heart failure

congestive heart failure ;CHf
muscle-wasting syndrome ; acquired heart failure ; Fontan
Frailty ; elderly ; adverse health
ED visits ; CHF ; intubation rates
bisoprolol ; mortality
health Buddy program ; telehealth system ; care management
Medicare fee-for-service ; hospitalization
physician continuity ; conditions ; hospital discharge
therapeutic ; heart failure
PSSS ; social support ; btes
defense mechanism ; cardiac stress ; β-AR drive
chromatin subproteome ; mouse heart
co correlated ; septal wall CS ; AVd variation ; free wall CS ; VVD
LV ; strain rate ; echocardiography ; baseline
death ; transplantation ; circulatory assist device
biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
etiologic ; acute RV failure ; left ventricular dysfunction
cPCs ; functional capacity ; heart failure ;HF
inhibition of protein kinase ; soluble guanylate cyclase ; contractile response
circulating progenitor cells ; outcome ; heart failure patients
stress doppler echocardiography ; pulmonary hypertension
systolic ; diastolic ; mitral leaflet motions ; organic lesion
morbidity ; mortality ;HF
ctnt ; NT-probNP ; HF risk prediction
t test ; cis ; regression
radiological ; HF
inhospital mortality ; bNP level
Mortality ; aCS
right ventricle ;RV ; cardiac function ; medical
costs ; heart failure ;HF
RV dysfunction ; weight loss ; fat/lean body mass ratio
HR reduction ; beta blockers ; exercise capacity ; hFrEF
cardiopulmonary exercise variables ; heart failure
proof-of-principle cohort study
i-mib ; myocardial washout
myocardial diastolic dysfunction ;DD ; collagen deposition ; titin modification
death ; hospitalization ; heart failure
baseline ; ST2 ;interquartile range
black race ; mortality
Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
therapeutic ; fluid overload
Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
social support ; exercise adherence
pressure ulcers ; surgical patients
HF ; valve plasty ; MS ; mVA
PD ; refractory ; end-stage congestive heart failure ;CHf
insurance ; comorbidities
beta blockers ; mortality ; heart failure
transcatheter ; surgery
futility ; data ; monitoring board
diagnostic procedures ; complication
chelation regimens ; heart iron ; risk
MT ; abdominal problems
test-retest reliability ; Timed up & go test ; chronic organ failure
NYHA
follow-up
mortality
Left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; left ventricular assist device implantation
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
functional capacity ; walk test
HFPEF ; dietary sodium restriction ; ventricular ; vascular stiffness
magnetically Levitated Left Ventricular Assist system for Treating Advanced HF
CHF atrial explants ; c-Kit ; cells ; sham explants
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
Heart failure ; western society ; cardiovascular diseases
extracorporeal membrane oxygenation ; recovery ; infarction-related refractory right heart failure
clinical ; laboratory ; echocardiographic ; invasive hemodynamic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
California office of statewide health planning and development Patient discharge data
Fontan failure ; systolic ventricular function ; liver disease
hospitalized older adults ; HF
apoptosis ; pacing-induced dilated cardiomyopathy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac
perioperative
economic impact ; af ; heart failure ; province of Québec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
bundle-branch block ;LBBB ; non-LBBB
protein levels ; western blot ; DNA fragmentation ; TUNEL ; autopsy samples
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation
EH ; CH ; cardiac filling pressures
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
cutoff level ; NT-probNP ; survival
human heart failure ; protein kinase ; subunit expression ; post-translational state
HF
Seattle Heart Failure model
dopamine ; nesiritide strategy
chemical instability ; cogeneration ; nitrite ; vascular effects
neurological ; cardiovascular event-free rate
cox regression ; cardiovascular events ; psoriasis
cp ; HF
HDl-induced NO production ; flow-mediated dilatation ; ET
patients ; aHF
preserved systolic function ; therapeutic
bets ; mouse TAC model ; human HF
cost-effective ; health interventions
cardiac nurses
procedures
transfusion ; mortality rates
Czech Republic
MAD-cRT ; device
study closure
UM/VA ;VA-RT
heart failure ; exposed group
Western blots ; monoclonal antibodies ; ser83 phosphorylation ; HF
preoperative serum albumin levels ; left ventricular assist device implantation
New York Heart association ; walk test ; quality-of-life
MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
pathophysiology ; HF ; medical
ED physicians ; New Jersey ; New York
psoriasis ; smoked ; diastolic blood pressure ; body mass index
exercise intolerance ; heart failure
echocardiography ; baseline ; shunt implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
cox models ; ST2 ; functional capacity
TM interventions ; sts
treatment group effects ; HRQoL
NT-probNP ; circulation ; HF
energy metabolism ; heart failure ; hypertrophied heart
MS ; LV dilatation ; functional MS
PAD ; ankle-brachial index
isolated HR reduction ; ivabradine ; TAC
baseline ; mechanical cardiac support ; renal function
ecmo group ; VAD ; ecmo+VAD groups
mortality ; morbidity ; cancers ; health-care budget
anticoagulation ; therapy ; underlying heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
heart failure ; systolic heart failure
baseline ; rhythm-control ; rate-control
hemoglobin levels
functional MS ; medical ; surgical
HF epidemiology ; health service ; HF ; LA
Heart failure ;HF
heart failure ;HF
CF lVAD ; AI ; heart failure
anemia ; heart disease
left ventricular dilatation
ventricular assist devices ; device therapie
device
renal dysfunction ; mechanical cardiac
HF
computing readmissions ; hospital rankings ; pay-for-performance
cf
PB ; HF ; central pattern generator
nontreatment ; primary care clinicians
serum factors ; coagulability
icd

bNP ; NT-probNP ; heart failure
Cardorespiratory ; body mass index ; heart failure mortality ; Cooper center
pro-adrenomedullin ;MR-proADm ; fm

Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
predictors of mortality ; implantable cardiac defibrillator
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
physical activity ; cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
systolic HF ; unclear etiology ; coronary angiography
atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control strategies
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Circulating fragments ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
end-stage heart failure ; implantation ; long-term ventricular assist device
HF ; cardiac murmurs ; reduction ; blood pressure
receptors ; adenyl cyclase ; differential g-protein coupling
HF ; spontaneous VT ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate II
TUg test ; advanced COPd ; CHF ; cRF
signaling pathways ; pressure-overload-induced heart failure
Nursing ; social mandate ; accountable ; outcomes ; nursing care
TREATMENT ; hemodynamically unstable ; cPR
isoproterenol ; cXL-1020 ; myocytes ; hearts
b ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
autonomic modulation ; repolarization instability ; heart failure prone ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
exercise intolerance ; chronic HFPEF ; quality of life ;QOL
energy substrate metabolism ; working hearts ; aac
SCHfi ; clinical practice
rule ; CAD ; severe CAD
diabetes mellitus ; cardiovascular disease
cvd ; psoriasis
haemodynamic ; pulmonary ; peripheral abnormalities
prediction rule
Rotterdam study ; psoriasis ; cardiovascular outcomes
HR ; tNF antagonists ; nbDMARD
aCS procedures ; MT ; VAD
general hospital ; cardiac specialty hospital ; south dakota
medical records
ecmo group ; egFR ; egFR
administration ; trastuzumab ; CHF
acute HF ; outline
research ; biomarker-guided clinical trials
hospitals ; metric

sudden cardiac death ; athletes
HF-related cachexia ; RV function ; body composition
hospital mortality
hospital length of stay ; rehospitalization
cognitive impairment ; mortality
sonographic ; histological ; functional abnormalities
natriuretic peptide levels ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; acute kidney injury
bNP levels ; PAD ; bNP ; HF
sympathetic ; parasympatic activity ; HF
EH ; systolic blood pressure ; renal impairment ; hypertension
race ; outcomes ; exercise training ; ambulatory HF
mouse ; HF model ; transition ; compensated LV hypertrophy ; HF ; hh
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure admissions
chronic myocardial ischemia ; heart failure ; therapeutic
HFpEF ; adverse outcomes
mechanical cardiac support ; renal function ; end-stage heart failure
revascularization ; catheter-based revascularization
baseline hgb ; exercise training ; kccq
Morpholino-based knockdown ; nucleolin ; protein expression ; morphological
clinical prediction rule ; CAD ; systolic HF
pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
MS ; medical treatment ; HF ; MS ; medical treatment
parasympathetic function ; HF evolution
medical ; HF ; HF ; ms ; mVA
jugular venous pressure ; peripheral oedema ; volume
Heart failure ;HF
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; biventricular
mineralocorticoid receptor antagonists
hereditary ; congenital abnormalities ; heart ; nontraumatic death ; sport
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
isolated HeartMate II lVAD
practice ; evidence-based practices
health insurance ; health system ; u.s. Food and drug administration
cutoff value ; NT-probNP testing ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status
albumin levels ; lVAD ; postoperative survival
cytoscape ; daVID
cardiovascular conditions ; HF
patient safety
HF-induced remodeling ; EMd prolongation
right heart circulation ; right heart failure
Raf-MEK1/2-ERk1/2 signalling pathway ; remodelling
mi ; late-onset ; MI ; HF
bisphosphonate ; heart failure
costs ; survival
commissioning ; hospital ; community-based programmes
clinical care ; maladaptive molecular
Xanthine oxidase inhibition ; left ventricular systolic ; diastolic function ; cardiac volume overload
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
heart failure ;HF ; Heart Failure adherence ; retention Trial ;HARt
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha ; quality-of-life score
myocardial infarction ; left anterior descending coronary artery occlusion
hapEF ; breathlessness ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; onset of heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; veGF signaling pathway
myocardial ischemic events ; cardiac resynchronization therapy
report ; aortic valve surgery ; new-onset post-LVAD AI
unloading of the heart ; isolated HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; atheromatous coronary disease
Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
rehospitalization ; medicare fee-for-service ; discharged ; skilled nursing facilities
HF hospitalization ; cRT ;hazard ratio
palliative ; patients ; advanced disease ; therapeutic
diagnostic test ; HFpEF ; medical history ; physical
oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
Resistin ; circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant
medications ; outpatients ; heart failure ; NCd PINnaCLE
nonselective ; beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure


Intravenous iron ; heart failure ; iron
heart failure ; Emergency department ;ED ; ED volume ; patient outcomes
conditions ; maladaptive remodelling ; heart failure
non-ischemic ; ischemic heart failure
psoriasis ; systemic ;UV
RV dysfunction ; weight loss ; abnormal body composition ; HF

trial
clinical ;prognostic ; diastolic dysfunction ; HFPEF
β-Adrenergic receptor blockade ; hospitalizations ; heart failure ;HF
right ventricle overload leads ; stroke volume ; left ventricular ejection time ; lVET
NT-probNP ; HF ; immunoprecipitation ; mass spectrometric
Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
PD ; hospitalizations ; therapy ; severe end-stage HF
pulmonary hypertension ;PH ; heart failure
robot-assisted gait therapy ; Lokomat® system ; heart failure
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
ET ; HDL function ; CHF-NYha-IIIb ; HDL function
Cardiac failure ; diabetes ; diabetes ; heart failure
exertion ; exercise ; hemodynamic status
lVET ; death ; ICU
congestive heart failure
aIM ; implantable cardioverter-defibrillator deactivation
mitochondrial structure ; sarcomeric microstructure
heart failure ; ejection fraction
gut ; inflammation ; dietary interventions ; heart failure
pp ; aCR ; CMS
mortality ; LCx ; LAD ; two-vessel disease model
CHF ; emergency department ;ED ; intubated
CHF ; therapeutic interruption ; activated neurohormonal systems
zf1 rats ; heart failure ; preserved ejection fraction
physician ; follow-up ; discharge ; death ; readmission ; heart failure
impact of heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
arterial tonometry ; lVET ; precapillary PH ; heart failure
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
mutant mice ; hand2 ; heart muscle cells ; pathological hypertrophy
transoesophageal echocardiography ; shunts ; thrombosis ; migration
uptitration ; heart rate ; renal function ; spironolactone
dialysis patients ; echocardiographic outcomes
microRNAs ;miRNAs ; pathogenesis ; heart failure
PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
ambulatory HF ; left ventricular ejection fraction
white rabbits ; renal DNx ; pacing-induced CHF
QT variability ;QTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
Beta-blocker dose ; resting HR
t1-mapping mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
cardiovascular ; baseline
processes of care delivery
psoriasis ; cardiovascular disease ;CVd
AMI mortality rates

proteins ; strong acid
Rhythm control therapy
cutoff ; e/e'septal ; negative likelihood ratio
costs ; clinical trials
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
LV diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance postcontrast ; heart failure ; preserved ejection fraction
myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
RAS-blocker uptitration ; hFrEF ; HFpEF
Hemoglobin ; exercise training ; health status ; chronic heart failure ; HF-action
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
Plasma samples ; HF
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic responses
risk ; heart failure ; CLCNKA sNP
GDMT ; control group ; GDMT ; BAT
baseline ; resting HR
transduction pathways ; signalling proteins
alendronate ; alendronate ; heart failure
cardiovascular disease ; dRS
index admission ; index admission
inappropriate therapy
beta-blocker therapy
heart failure ; bisphosphonates
frailty ; risk ; heart failure ;HF
miRNAs ; cardiac remodeling ; heart failure
medical management ; HF ; infancy
clinical diastolic dysfunction ; cause mortality
Alphalisa ; immunoassays ; NT-probNP
Fontan ;SAF
c-statistics ; biological phenotype ; deficit index
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxicity ; doxorubicin ; anti-neoplastic ; cancers
aCS ; oHT bridged ; transplant ; MT ; VAD
natriuretic peptides ; emergency ; ambulatory
RAS- ; β-blocker ; uptitration
β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
HF ; rheumatoid arthritis ;RA
expression ; Bax ; bcl-2 proteins ; dogs
HF ; CMS metric ; conditions
regulation of feeding ; anti-inflammatory effects ; CHF
drugs ; HF ; ejection fraction ;HFrEF
Crude rates of severe hyperkalemia ; acute kidney injury ; spironolactone
Renal denervation ;DNx ; CHF ; protective mechanisms
MT ; VAD groups ; aCS ; operations
hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
heart failure ; left atrial pressure ; hospital admission
Heart failure ; preserved ejection fraction ; hff ; failure of cardiovascular reserve
LV diastolic dysfunction ; mechanism ; hff
physician follow-up ; discharge ; physician continuity ; heart failure
ambulatory iCD patients ; predictor ; mortality ; multivariable regression
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; solid Ehrlich carcinoma
myxomas ; cardiac benign tumors ; left atrium
fes ; preserved ejection fraction ;HFpEF
bNP ; NT-probNP ; coronary artery disease ;CAD
exercise group
NT-probNP ; assays
clinical variables ; ecCT
peak aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
process redesign
myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure mice model ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
shortened lVET ; ICU admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; death ; left ventricular ejection fraction
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
tissue doppler imaging ; left ventricular ; filling pressure ; systolic heart failure
zSF1 group ; obese ; zSF1 groups ; hypertensive ; diabetic
heart failure ; preserved ejection fraction ; hff
Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
myocardial pde2 ; intracellular antiadrenergic ; strategy ; HF
spironolactone ; medications
HF hospitalization ; died
ip ; heart failure ;HF ; death ; cRT-d
pharmacologic ; clinical trials ; pharmacologic
mechanical dyssynchrony ; QRs complex ; cRT
coronary occlusion ; collateral growth
carotid intima-media thickness ; psoriasis
transfusions ; heart disease
exercise ; peak VO2 ;joint effect
PVf ; PB cycle ; recovery period ; low BP
chronic heart failure ; Hungary
RV dysfunction ; cardiac cachexia
remote monitoring ;RM ; heart failure
ecg parameters ; cRT
sst2 ; low-dose BB ; cardiovascular event rate
breast cancer ; trastuzumb-related CHF
HF remodeling ; EMd ; dyssynchronous failing heart
acute heart failure ; aHF ; symptoms ; heart failure ;HF
angiogenesis ; post-myocardial infarction heart ; progression ; heart failure
clinical ; aldosterone antagonist ; heart failure
surgery ; HF ; hypertension ; vasodilators ; diuretics
Genetic ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR reduction ; beta-blocker therapy
pde2 ; failing hearts ; acute β-AR stimulation
psoriasis ; atherosclerosis ; cardiovascular ; psoriasis
anemic ; iron-deficient adult patients ; heart disease
heart failure ; hospitalisation
egFR ; diuretics ; uncontrolled hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
EO-CFUs ; mortality ;hazard ratio
Point-of-care systems ; NP levels ; ED ; outpatient settings ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
black race ; HF hospitalization ; cardiovascular mortality
exercise ; cardiac disease ; heart failure
hfff
physician adherence ; HF cPGs
HF ; HF ; HF mortality
HDL function ; CHF ; ET ; HDL-mediated vascular effects
coronary artery disease ; systolic heart failure ; unclear etiology
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
ea ; arterial compliance ;TAC ; end-systolic elastance ; ees
biventricular support ; HeartMate ; lVAD ; centriMag RVAD ; mortality ; hospital discharge
Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ;CABG
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
baseline ; isoprenaline infusion ; SDQT ; hNorm ; HF
Renal dysfunction ; cardiovascular events ; postoperative months ; primary isolated caBG
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
egf ; VAD group ; ecmo ; VAD group ; ecmo
CHF ; international classification of Diseases ; Ninth revision
RV dysfunction ; body mass index ; fat mass index ; cachexia
baseline ; cRF ; HF mortality risk ; HF risk factors
Robot-assisted gait therapy ; Lokomat® system ; heart failure
cardiac growth ; plasticity ; disease recapitulates ; developmental chromatin remodeling
idiopathic dilated cardiomyopathy
dopamine ; nesiritide
MEDline ; EMBAse ; cochrane ; clinical trial registries ; technical advisors
Clinic ; nonprescribing ; chart review
HF ; HF
baseline Ea ; TAC ; HR ; ees ; ivabradine ; placebo-treated patients
care management ; content-driven telehealth technology ; health outcomes ; high-cost Medicare
ERC ; pure epicatechin ; muscle function
biomedical reasons ; nonprescribing
myocardium ; post-translational ; pKA ; downstream signaling
atrial fibrillation ; carvedilol ; metoprolol
grounded theory ; heart failure ; implantable cardioverter-defibrillator
functional MS ; valve plasty ; degenerative MR ; LV
HeartMate II insertion ; biventricular ; HeartMate II implantation
end stage heart failure ; public health ; europe ; North America
ST-segment-elevation MIs ; Killip class
heart failure ; mechanical support devices ; Cardiology-Cardiovascular Surgery ; report ; Heart failure
s3991 ; elastic N2Bus segment ; s12884 ; pevk segment
self-Care of Heart Failure index ;SCHfi ; psychometric profile
proteomics ; chromatin-associated proteins ; detergent
HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; mechanism of cardioprotection
pharmacologic ; acute HF ; adverse event rates ; chronic HF
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
cXL-1020 converts ; hno ; inactive ; cXL-1051
tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
ejection fraction
gls ;HR ; cv events
exercise ; diet
risk-adjusted mortality ; hospitals
magnetic ; research
physician adherence ; class I recommendations
HF ; drug treatment ; PAf biosynthetic enzymes ; lyso-PAf-AT
epidemiology ; myocardial infarction ;MI ; heart failure ;HF
cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker hypo-response
RAS ; hypertension ; nephropathy ; congestive heart failure
admission ; serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
bem-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; NCT00180271)
baseline ; NT-probNP ; MR-proanp ; MR-proadm
isoelectric focusing ; RIα ; ser77 ; ser83 ; vivo phosphorylation sites
ratio ; SDQT ; SD ; RR intervals ;SDr ; QTV ; heart rate variability
aUCs ; e/eseptal ; e/emean ; s'septal ; QRs
Logistic regression models ; secondary outcome ; death ; confounders
IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; synchrony
readmission rate ; hospital ; congestive heart failure
diuretics ; HF-related morbidity
hospital ; readmission rate ; heart failure
devices ; gastrointestinal bleeding
cardiac events
egf ; VAD group ; ecmo+VAD group ; renal function
sst2/low-dose BB ; sst2/high-dose BB
CHF visit rates ; ED visits ; CHF patients intubated
physical volume ; mortality ; HF ; noncardiologist
zebrafish ; Nucleolin ; genomic reprogramming events ; disease
LV ejection fraction ; PCWP
HF ; AMI ; high mortality
emergency department ; acute heart failure ; trials
cardiopulmonary exercise test ; quality of life score ; muscular strength ; peak quadriceps force
public health ; air pollution ; industrial areas ; cardiovascular health ; hospitalisation ; death
ecg ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; Tuscany
HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Morbidity ; mortality ; HFpEF ; HF ; EF
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
heart failure ;HF ; inpatient ; outpatient models
molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure ; devices
erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; exercise tolerance ; heart failure
report ; mitral valve plasty ; degenerative mitral regurgitation
in-trial resource ; unit costs ; Québec ; health insurance board ; costs ; Ontario case costing Initiative
BET ; bromodomain-containing protein 4 ;BRd4 ; cardiac tissues
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
readmission rate ; follow-up
end-stage heart failure ; pediatric mechanical cardiac
economic models ; lVAD ; outcomes
echocardiographic score ; cRT response
ejection fraction
AF ablation
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
t1-mapping sequence ; tidal respiration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare inpatient data ; HF admissions ; acute care hospitals
catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROSE acute heart failure
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
mouse HF model ; hh ; salt loading ; uninephrectomy ; ANG II infusion
HF ; preserved ejection fraction ; pEF ; uptitration ; hospitalization
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk model
echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
baseline serum creatinine level ; serum potassium level
chromatin subproteomes ; heart failure ; mechanisms ; proteins ; chromatin structure
Hum- retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes ; Retn
anemia ; chronic heart failure ;HF
university of connecticut Heart Failure center ; cardiologist ; heart failure
NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
RV failure ; management strategies ; intrinsic left ventricular dysfunction
PD ; weight loss ; diuretic response ; peripheral edema
Chronic heart failure ; transforming growth factor ; beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
HFpEF ; kccq ; health status ; prognostic
HeartMate II lVAD ; temporary centriMag RVAD
exercise ; heart failure
HF ; MI ; preserved ; ejection fraction ;EF
Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
nbDMARD ; tNF antagonist ; baseline
trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR effectors ; protein kinase ; er kinase ;perk ; calreticulin ; CHOp ; HF tissues
myosin binding protein-C phosphorylation ; ser23/24 troponin I phosphorylation ; HF
electrocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory
Phosphodiesterase-2 ; failing hearts ; blunts ; beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype status
hff ; exercise performance ; resting HR ; beta-blocker therapy
baseline ; pf ; activity ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
randomised-controlled trials ;RCts
cox hazard models ; ESRD ; to death ; ESRD ; death ; predictors ; ESRD
preoperative renal dysfunction ; early risk ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
heart failure ; heart failure nurses ; cardiology ; mortality
HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
direct observation ; rheumatic ; MS ; mVA
women ; health initiative ; HF
CHF-developed infarcted animals ; left ventricle ; end-diastolic pressure
RV ; pathophysiologic mechanisms ; RV dysfunction
dialysis-dependent patients ; HF ; cRT implantation
Peak ; oxygen ; pulse
economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes ; acute hospital
post-hct CHF ; hCT ; City of Hope

pigs ; vena cava ;IVc ; snared ; co
doxorubicin ; ip ; serum resistin levels ; Hum-retn mice
costs ; high-volume physicians
nutritional abnormalities ; CHF ; fat ; carbohydrates ; proteins ; water
deactivation
aldosterone receptor antagonists ; morbidity ; mortality ; symptomatic systolic heart failure
scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
albumin levels ; inflammation ; hepatic function ; lVAD implantation
right ventricular ;RV ; insertion ; left ventricular assist device ; lVAD
tAPse ; PASp relationship ; downward regression line shift ; nonsurvivors ; PASp ; tAPse
cox proportional hazards models ; health behaviors ; health status ; hazard ratios
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
CV deaths ; non-fatal stroke ; hospitalisations ; heart failure
hearts ; Mena ; cardiac injury ; Mena ; HF
therapeutic ; biomarkers ; molecular dysfunction ; chronic HF
ST2 ; reclassification ; risk ; c statistic ; net reclassification ; discrimination
gls ; index beat method ; cv ; cox proportional hazards
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD group ; ecmo+VAD group ; ecmo group
Ambient air pollution ; cardiovascular health ; acute myocardial infarction
kccq ; Kaplan-Meier curves ; death ; all-cause hospitalization
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
AMI ; heart failure ; kidney infection ; UTI
global proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
IC ; multicenter Automatic Defibrillator Implantation ; Trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI ; HF
health Buddy program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
medical hospitalization ; HF
HF ; admission ; discharge
neurohumoral blockers ; HF ; co-morbidity burden
Age-dependent effect ; left ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; ISrael
inhibition of vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy ; cardiac failure
prediction rule ; CAD ; severe CAD
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
apoptosis ; pathogenesis ; heart failure
diagnostic procedure ; treatments
diuretic efficacy ; neurohormonal activation ;congestion-like ; fluid overload
uPR ; na+ channel mRNA splice ; reduction ; cardiac na+ current ; human HF
LVEF ; LVEF
lVAD ; transplantation eligibility status ; budget
BETs ; transcriptional pause release ; transcription ; pathological stress
ecg ; atherosclerotic CAD ; sudden cardiac death
HF ; index AMI ; adjusted hazard ratio ; 1-year mortality
cRT-d ; IE ; defibrillator-only therapy
HR dynamics ; HR variability ; risk stratification
cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling
speckle tracking echocardiography ;STE ; biVP ; right ventricular pressure overload ;RVPO
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
percutaneous coronary revascularization ; hemodynamically ;ICU
obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
sex ; EF ; bNP ; HF ; bem ; bNP ; bNP ; sex ; EF
perk inhibition ; full-length sCN5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
Mena expression ; HF ; Mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ang II infusion mouse model ; cardiac function ; mice ; HF
echocardiographic score ; LV reverse remodeling
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
dose uptitration ; HR reduction
bottleneck stent ; myocardial infarction ; antiplatelet medication
ANS mice ; LV fractional shortening ; lung weight
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; augment cardiac output
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
incident systolic heart failure ; spironolactone ; hospitalization
Rad variant ;Q66p ; congestive heart failure ; humans
regulation of programmed cell death ; degs
atrial fibrillation ; atrial fibrillation ; Stroke prevention Trial
etiology ; comorbidities
intestinal morphology ; permeability ; absorption function ; CHF
exercise ; anaerobic metabolism ; peak respiratory
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
peak work rate ; peak quadriceps force
proteins ; cardiac hypertrophy ; failure ; proteins ; Nucleolin
idiopathic dilated cardiomyopathy
patients ; high-volume physicians ; readmission rates
NP measurement ; POC measurement ; NPs ; clinical care delivery ; emergency
randomized trials ; follow-up
Kansas City ; cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
Tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; right ventricular contractile
biventricular support ; HeartMate II ; lVAD ; centriMag right ventricular assist device ; rVAD
Blood pressure ; arm cuff ; stroke volume ; sv ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic
Caucasian ; sNP rs10927887 ; Ka renal chloride channel gene ;CLnKA
exercise training ; HF patients ; exercise training therapy
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; death ; fibrosis ; inflammation
HF-action cohort ; baseline hgb ; baseline HRQoL ; kccq
Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
right ventricular ;RV ; body composition ; advanced heart failure ;HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
American college of Cardiology ;American Heart association ; RAS
case report ; functional MS ; valve plasty ; degenerative MR ; LV
EO-CFUs ; cd34 ; vegf2 ; cells ; nondiabetic patients
implantable cardioverter-defibrillator deactivation ; physicians ; heart failure
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
Frailty ; heart failure ;HF ; biological
LV remodeling ; diastolic ; XO inhibition ; hospitalizations ; severe heart failure
SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
borderline ; EF
t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
bp ; inhospital mortality
is ; cRT-d recipients ; heart failure ; death
expenditure ; health per capita ; gross national income per capita ; HF ; LA
bt ; DT ; cost-effectiveness limits ; bt ; standard practice ; patients
AF ; pharmaceuticals ; hFPEF
blood pressure control ; lipid-lowering therapy ; smoking cessation ; RAS
cost-effective
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
Implantable cardioverter-defibrillators ;ICds ; mortality ; cardiac resynchronization therapy ; cRT
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
low-sodium DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; preserved ejection fraction
HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
exercise-induced PASp ; low PASp
skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
physical volume ; patients ; procedures ; HF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
eplerenone ; HF-ref ; inducing hyperkalemia ; wRF
mitochondrial complex ; activity ; post-aac ; ratio of phosphocreatine ; ATP
sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
frail ; intermediate frail ; biological
QRs morphology ; cardiac resynchronization therapy ; cRT
hff ; outcome-monitoring phase ; cardiac event
RM ; discharged ; unplanned admission ; heart failure
emergency department ; acute heart failure ; aHF
embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
standard error of measurement ; mDC
LBBB ; implantable cardioverter defibrillator-CRT ; primary outcome
isolated heart rate ;HR ; ivabradine ; afterload ; patients ; systolic heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis
Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure ; QRs
perk activation ; scn5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel ; m7 ;TRp7) channel mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network ; toronto
exercise-induced PASp ; pulmonary hypertension ; right ventricular contractile reserve
miania ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
Cardiovascular outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ; RAS
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean and Dietary Approaches ; stop Hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ; HF
multiparametric echocardiographic score ; reverse remodeling ; cRT
Yorkshire swine ; pacemakers ; ventricularly paced ; induce heart failure
renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
HF ; HF ; epidemiology ; SH ; cd ; rheumatic fever
patient-level regression ; risk-adjusted mortality ; readmissions ; costs
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese ; hFPEF
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; molecular pathways
guideline-recommended medications ; heart failure ; reduced ejection fraction
HFpEF ; diastolic ; filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtttMena ; cardiac pathology
antiplatelet agents ; anticoagulants ; vascular diseases
right Heart foundation ; right heart failure
NP levels ; diagnostic evaluations
LBBB ; QRs ; implantable cardioverter ; defibrillator-CRT
echocardiography ; cardiac diameters ; cardiac function ; b-treated ; vehicle-treated rats
electronic databases ; MEDline ; EMBAse ; PsycINFO

factorial trial
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
af ; severe heart failure ; financial burden
body weight ; FM ; fm ;cc
r. Cluster
ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; preserved ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
mice ; cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
baseline ; hgb ; baseline ; kccq scales ; hgb ; exercise training ; HRQoL
outpatient assessments ; patients ; heart failure ; hospital discharge ; readmissions
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; preserved cardiac index
myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
crude ; adjusted ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels ; unfolded protein response ; uPR ; scn5a ; electric remodeling ; HF
intermacs ; interagency Registry for mechanically assisted Circulatory support
allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament ca(2+) sensitivity
imaging ; systolic function ; HFpEF ; long axis function ; exercise
physicians ; advanced heart failure
concurrent HF ; 28-day mortality ; hazard ratio ; 28-day survivors
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone ; non-AAs
g-protein-coupled receptor kinase-2 ; desensitization ; downregulation
NT-probNP assay ; nonterminal epitopes ; central glycosylated
scn5a ; angII ; hypoxia ; exogenous variants induced ; uPR ; downregulation ; na+ current
isolated heart transplant
bp ; quartile of e/e ; diastolic dysfunction
rate ratio ; therapy ; comorbidities
rehospitalization ; Medicare ; claims ; Medicare ; post-acute care transfer policy
heart failure ; refill compliance ; etidronate ; alendronate
AT ; metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; HF mortality
et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
low-dose dopamine ; nesiritide ; decongestion ; renal function
guideline ; anemia ; iron deficiency ; MEDline ; cochrane Library
kccq ; internal consistency ; HFpEF ; cronbach
implantable cardioverter defibrillator-CRT ; non-LBBB ; QRs duration
clinical trials ; treatment strategies
alendronate ; etidronate ; raloxifene
Chemotherapy ; trastuzumab ; CHF ; international classification of Diseases ; healthcare Common procedure codes
contemporary heart failure ;HF ; therapies ; HF ; left ventricular ejection fraction ;LVEF
hART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
conscious dogs ; tachypacing-induced HF ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
mechanisms ; bone morphogenetic protein ; expression ; rRNA transcription ; shift ; heterochromatic chromatin
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
systolic HF ; Danish Heart Failure database ; new-onset ESRD ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; advanced heart failure ; pump dysfunction ; pump replacement
ST2 ; amino-terminal pro-b-type natriuretic peptide
biventricular pacing ; biVP ; cardiac output ;co ; cardiac surgery
fully magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure model-predicted survival
New York Heart association ;NYHA ; chronic heart failure ; reduced ejection fraction
AlphaLISa immunoassays ; antibodies ; N ; c termini ; circulating NT-probNP
serum levels ; creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; regulation ; Rad Q66p ; rGK protein
myocyte hypertrophy ; heart failure ; global gene expression ; DNA accessibility ; genomic scale
performance ; hospitals ; extreme deciles ; longitudinal performance
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
neurohormones ; adipokines ; body composition ; CC ; fat free mass ;FFm ; fat mass ;FM
cardiac plasma membrane levels ; s1PR1 ; counterbalance ; β1AR overstimulation ; heart failure
Sprague-Dawley rats ; sham ; aCF ; allopurinol
t1 changes ; myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
BB therapy ; sst2 measurement ; chronic heart failure
cRT group ; control group ; hazard ratio
ESRD ; outpatients ; systolic HF ; egf
tAPse ; PASp relationship ; length-force relationship ; RV function ; LV dysfunction
TUel assay ; apoptotic cells ; TUNEL-positive cells ; paced groups
hano donor ; myocardial function ; HF
biventricular support ; rVADs
congestive heart failure ; midwestern state ; South dakota
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium ; conditions ; workload
MT group ; operation
cox proportional hazards models ; death ; transplantation ; LV assist device implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
correlation coefficient ;ICc ; kappa coefficient ; standard error of measurement ; md
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; controlled Trial Investigating outcomes ; exercise TraiNing ;HF-action
stockholm national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
Renal dysfunction ; heart failure ;HF ; dysfunction ; end-stage renal disease ;ESRD
regression analysis ; echocardiographic score ; LV reverse remodeling ; LV ; end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; PAD
readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Fontan circulation
biological phenotype ; medical records ; frailty
SDQT ; HFVT ; hNorm group ; acute β-adrenoceptor blockade ; esmolol
Cardiology practices ; national Cardiovascular Disease Registry ; practice innovation ; Clinical Excellence
sts HH ; medical ; office hours ; all-cause mortality ; discharged patients ; heart failure
induced myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
transitions of care ; self-management training ; out-patient follow-up ; health care system
CHF ; cardiac explant c-Kit ; progenitors ; regulation
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
report ; hno donor ; cXL-1020 ; isolated myoctyes ; intact hearts ; heart failure ;HF
drug-free
leaflet ; serial evaluation ; MS ; subvalvular ; dynamic ; annular MS ; fixed ring
race ; chronic heart failure ;HF ; exercise training response
histological ; capillary ; coronary perfusion ; b-treated ; ad-flk rats ; b-treated ; ad-c rats
physician volume ; mortality ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
protocol-driven POC testing ; NP ; patient consultation ; ED
heart failure ; CHARM programme ;Candesartan in Heart Failure assessment of reduction in Mortality and Morbidity
Troponin t ; N-terminal pro-b-type natriuretic peptide ; heart failure risk ; atherosclerosis
left-to-right interatrial shunting ; patients ; heart failure ; ejection fraction
physical ; bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance t1 ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction ; heart failure ; reduced ejection
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress induced ; doxorubicin cardiotoxicity
heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass
MI-induced decreases ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV internal diameter ; metoprolol
American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
hfef ; caloric restriction ; aerobic exercise training ; peak VO2
economic analysis ; Patient management Interventions ; Heart Failure cost-efectiveness model ; cost-effectiveness ; disease management programs ; heart failure
HF registry ; HF ; EF ; HFpEF ;EF
BAT ; N-terminal pro-brain natriuretic peptide ; HF
HR variability ; mortality ; AMI ; CHF ;LV dysfunction
exercise ; cell senescence ; active individuals ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
cardiac transplant ; ecCT ; transplant pool ; donors ; recipients ; transplant
Fontan ;PF ; catheterization
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure ; morbidity ; mortality
anemia ; HF ; health-related quality of life ;HRQoL ; HF
cell therapy ; chronic heart failure ;CHf ; explant-derived progenitor cells
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
acute RV failure ; pulmonary embolism ; mortality
serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 titrated ; high-dose BB ; cardiovascular event rate
Rad Q66p ; cardiomyopathy ; mechanism ; l-type channel-dependent
altered ventricular structure ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
baseline ; SDQT-to-SDr ratio ; HFVT ; HFVT ; hNorm groups
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
exercise ; medical Therapies ; Cardiac Function ; shortness of Breath Due to Lung congestion ;ACTRN
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; preserved left ventricular ejection fraction
tachycardic response ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD model
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation ; ultrastructural
cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; acute kidney injury
mortality ; mortality ; cardiovascular mortality ;HF hospitalization ; cox models ; exercise training
neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; b-type natriuretic peptide
tpse ; PASp relationship ; nonsurvivors ; hFrEF ; HFpEF ; prognostic resolution
HF-action ; HF ; ejection fraction ; usual care ; exercise training
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development ; disease
NT-probNP levels ; admission ; all-cause mortality ; acute HF
haematopoietic cell transplantation ; ght ; congestive heart failure ;CHf ; pre-HCT ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic ; mitochondrial dysfunction induced ; cumulative administration ; doxorubicin ; rats
in vivo inhibition ; mir-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium ; heart failure
Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
postoperative survival ; preoperative hypoalbuminemia ; normal albumin
bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitivity ; time domain ; heart rate variability ;HRv ; CHF-inv ; sham-inv ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; refill compliance
nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
carvedilol ; β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
baseline ; cardiac transplant survival ; ecCT
HF ; AMI ; pna ; mortality
dietary recommendations ; heart failure ;HF ; non-HF ; HF
arrhythmia substrate ; AMI ; HR variability ; arrhythmia events
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate ; human resistin
hypertension ; compensated HFPEF ; DASh ; srd ;target sodium
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical
high-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
dgs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing outcomes classification ;noc
8-fluo-cAMP binding ; wild type ; phosphomimic ser77 ; ser83 ; ser83 ; mutant ; RIα proteins ; double mutant ; WT RIα
preoperative albumin ; mortality ; lVAD implantation
systolic heart failure ; QRs duration ; cRT ; rate of death ; hospitalization ; heart failure
cox regression models ; propensity score decile ; oral glucocorticoid ; HF hospitalisations ; loop diuretics
functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
Dialysis ; HF hospitalization ; hospitalization ; mortality ; HF
reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber shortening onset
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFt
statistical standards ; biomarker studies ; biomarker-guided clinical trial design ; multimarker-based strategy
SAF cohort ; abnormal liver texture ; nodularity
transplant ineligible patients ; PD ; HF volume management ; clinical ; post-PD initiation
Frailty ; biological phenotype ; weak grip ; physical exhaustion ; slowness ; activity ; unintentional weight loss
cRT-d ; IE ; IC ; cRT-d ; IEs
EDs ; discharge ; heart failure home ; low-volume ED cases ; readmissions ; repeat ED visits
acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; corporeal membrane oxygenation ; ecmo ; cPR ; ICU
report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
undiagnosed heart disease ; HF ; surgical palliation
heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; right ventricular dysfunction
cPCs ; early-outgrowth colony-forming units ;EO-CFUs ; circulating CD34 ; vEGFR2 ; CD133
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
continuous-flow lVADs ;HeartMate II ;HM II ; HeartWare ; bt ; DT
baseline EF ; EF ; blinded core laboratory
skeletal muscle mass ; relative appendicular lean mass index ; z-score
DASh diet scores ; mortality ; HF ; Mediterranean
quality of life ; all-cause mortality
bp ; inhospital mortality
cardiovascular diseases ; heart failure ;HF ; HF
heart failure ; left ventricular systolic dysfunction ; BB
CLnKA polymorphism ; arg83gly ; heart failure ; glomerular filtration rate ; reNAStur
ST2 ; functional capacity ; outcomes ; ambulatory patients ; HF
b treatment ; cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; b-treated ; failing hearts
Gene expression ; cultured cardiomyocytes ; jq1 ; drug abrogated ; induction ; phenylephrine-induced genes
exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
baseline ; post-DASh ; srd ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic measures
psychosocial factors ; exercise adherence ; Heart Failure Patients ; Heart Failure ; controlled Trial Investigating outcomes ; exercise training ;HF-action
derivation cohort ; coronary angiography ; primary diagnosis ; systolic HF ; unclear etiology
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ees ; ea
rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
angiotensin II ; angII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; induced ; scn5a
HF ; reduced ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
extracorporeal life support ;bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene ; mechanism of action ; heart failure
hearts ; tgtttMena mice ; wild-type littermates ; heart mass ; transgenic mice
hff ; exercise protocol ; respiratory gas ; baseline
guideline-recommended drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
wasting ; fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
hearts ; fish lacking ; Nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
black race ; chronic HF ; modifiable risk factors ; exercise performance ; HF hospitalization ; mortality ; exercise training
adverse event ; acute myocardial infarction ; congestive heart failure ; in-hospital adverse events
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hRetn ; human resistin ; mRNA ; protein expression
lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; Framingham ; Mass
FM ; plasma NPs ; total adiponectin ; baseline ; FM ; fm ; NPs ; adiponectin
withdrawal of sympathetic tone ; parasympathetic tone ; heart rate response ; intravenous bolus of metoprolol ; atropine
EH ; HFpEF ; pathophysiologically ; HF ; EF ;HFrEF ; hFrEF therapy
plasma collected ; HF ; immunoreactive NT-probNP ; N- ; c-terminally truncated fragments ; NT-probNP
beat-to-beat QT interval ; surface ECGs ; baseline ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion
trial ; limits of agreement
power spectral ; low-frequency ; high-frequency ;LF/HF ratio ; CHF-inv ; sham-inv ; sham levels ; DNx
contractility ; ventricular-arterial coupling ; ivabradine-treated patients
follow-up visits ; 30-day readmissions ; hospital quality improvement
N-terminal pro-B-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; postcontrast t1 ; hFPEF ; postcontrast t1 ; biomarker ; hFPEF
HF-action ; left ventricular ejection fraction ; New York Heart association ; IV HF ; exercise training
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; preserved ejection fraction
cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models ; survival ; health
Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
admission ; NT-probNP ; admission ; ED ; acute HF diagnosis
Peak oxygen consumption ;VO2max ; resting HR
heart failure ; sudden death ; noncardiac ; cardiac transplant
frailty ; health ABC ; short physical performance Battery ; hABC Battery ; Gill index ; incident ; HF
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
clinical prediction rule ; CAD ; angiography ; systolic HF
load-corrected chronotropic response ; heart rate ; baseline ; follow-up tests ; heart rate
hospital ; gastrointestinal bleeding ; died ; incessant ventricular tachycardia storm ; terminal heart failure
Catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail ; hawt ; Gill index ; HF
HF ; AMI ; adjusted odds ratio
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
Chronic β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
chronic pAH ; hospitalized patients ; acute RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
zf1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ;acf
free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
PF cohort ; New York Heart association ; SAF ; PF
comanagement ; clinicians ; patient preferences ; nonadherence ; medication
patients ; high-volume physicians ; mortality ; low-volume physicians
western Australian ; administrative health data ; HF ; AMI
report ; conditions ; turkey
ecs ; diagnosis ; heart failure
nursing-sensitive outcome measures ; science ; HF
miRNAs ; noncoding RNAs ; regulate expression ; genes ; untranslated region ; messenger RNA ; degradation ; translational repression
HFpEF ; ivabradine ; placebo ; double-blind
Cardiac c-K ; cells ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; pulmonary embolism ; diabetes ; chemotherapy
nurses ; pathophysiology ; HF ; medical management ; pathophysiologic state
empirically ; composite quality ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hfEF
heart failure ; preserved ejection fraction ;HFpEF ; health status
cox proportional hazards regression modeling ; IE ; hospitalization ; acute coronary syndromes ; coronary interventions
cyclic adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgm ; signaling ; failing hearts
RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ;nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
e ;septal correlated ; PCWP ; e/e ;lateral ; e/e ;mean
therapy ; atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
cp-recommended pharmacological treatment ; device ; self-care ; discharge ; left ventricular function assessment
gls ; LVEF ; sa ; adverse CV events ; prognostic benefit ; echocardiographic systolic parameters ; AF
ERC induced recovery ; DAPC protein levels ; sarcomeric microstructure ; markers ; Skm growth ; myofibre regeneration
signalling cascades ; microRNAs ; bhlh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
Rad Q66p limits ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ; LCx model ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD models
EH ; LV compliance ; lv ; end-diastolic volume ; LV ; end-diastolic pressure ; hg β coefficient ; CI
mv ; annular size reduction ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
hART ; New York Heart association ;NYHA ; hospitalized ; HF ; self-management counseling ; HF hospitalization
in vivo assessment ; cardiac function ;via echocardiography ; diastolic dysfunction ; e ; ejection fraction
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF pathogenesis ; HF
transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
Grading of recommendations assessment ; evaluation ;GRADe
HF
right heart circulatory failure ; mechanisms of disease ; right heart
influx ; l-type voltage-gated ca(2+) channels ; plateau phase ; ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes
bp ; glomerular filtration rate ; hypertension ; transmitral E-wave ;early diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic ; natriuretic peptides
β-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA ; downstream ; β-adrenergic receptor activation ; post-translational states
erythropoiesis-stimulating agent therapy ; venous thromboembolism
black race ; mortality ;hospitalization ;hazard ratio ; cardiovascular mortality ;HF hospitalization
percutaneous ; two-vessel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube ; bottleneck shape
CHF predictive model ; curve ;AUc ; genetic ;AUc ; clinical
logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; HF index
heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
centers for Medicare and Medicaid services ; cm ; hospital quality of care outcomes ; publicly ; mortality ; readmission rates ; penalties
cox proportional hazard models ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
logistic regression ; rule ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; pathological changes ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
hff ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
Randomized aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
incidence ; mortality outcomes ; heart failure ; acute myocardial infarction ; western Australia
CHF ; ght ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ;nonadherence ; salt intake
pathophysiological ; diagnostic ; prognostic
lVAD surgery ; albumin levels ; hypoalbuminemia
creatinine ;hazard ratio ; post-transplant
risk of death ; glomerular filtration rate ;odds ratio
scientific literature ; clinical studies ; HM II ; HeartWare patients ; economic evaluations ;HM II
low-dose dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
randomized trials ; HR variability/turbulence ; routine measurement ; HR variability ; turbulence ; risk stratification ; cardiac patients
lVAD therapy ; transplantation eligibility status ; device ; bt ; DT ; medical therapy
radial artery tonometry ; admission ; PH ; ICU
magnetically levitated centrifugal-flow chronic lVAS ; adverse event profile
eRK1/2 signalling ; signal ; scaffold protein drives ; kinases ; sequential phosphorylation ; effector molecules
breast cancer patients ; Medicare coverage ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas cancer Registry-Medicare databases
ejection fraction ; b-type natriuretic peptide levels ; hospitalized ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
diseased cardiomyocytes ; pde2 activity ; cgm synthesis ; nitric oxide donors ; pde2 inhibition ; β-AR responsiveness
l-dKO mice ; cardiac ; iRS1 ; iRS2 ; heart failure ; impaired cardiac energy metabolism ; p38α mitogen-activated protein kinase
ECs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser ; p70s6k-Ser
low PASp ; peak o2 per kilogram
sts ; HH ; HM ; sts ; TM
mouse ; ventricular myocytes ; sarcomere ; peak ca(2+) transient
administrative databases ; province of Alberta ; discharged alive ; hospital ; first-time diagnosis of heart failure
heart failure ; myocardial collagen ; tissue ; control ; heart failure
cRT on assignment ; time to death ; first HF hospitalization ;hazard ratio ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
relative risk ;RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ; CI ; adjusted hazard ratio ;HR
Medicare ; fee-for-service beneficiaries ; centers for Medicare ; Medicaid services ; propensity-score
physician adherence ; guideline ; heart failure ; clinical practice guideline ;CPg ; outcomes ; heart failure ;HF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural ; antitumor activity
kccq ; New York Heart association ; HFpEF ; HF ; EF
Rhythm control therapy ; af ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
acute heart failure ; renal dysfunction ; low-dose dopamine ; low-dose nesiritide ; renal function ; diuretic therapy
HF ; body composition ; skinfold thickness ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
Patients ; heart failure
aCP ; restrictive red blood cell transfusion strategy ;trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia
implanted left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ;DT
Caloric restriction ; aerobic exercise training ; Peak oxygen consumption ; quality of life ; Heart Failure ; Preserved ejection Fraction
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADIT-CRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; dose-related gradient ; HF risk ; HR
HR ; ivabradine group ; ea ; TAC
carvedilol ; inappropriate therapy ; metoprolol ;hazard ratio
ghm ; adjunctive treatment ; dCM ; heart failure
testosterone ; exercise rehabilitation ; CHF ; low testosterone status
peak VO2 ; change ; lean body mass ; thigh muscle ;intermuscular fat ratio
guidelines-Heart Failure ; HF ; borderline ;EF ; EF
economic analysis ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; cost-effectiveness ; disease management ; heart failure
HFPSI ; risk of death ; medical hospitalization ; HF ; outpatients ; HF resources ; health systems
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model ; PASp ; exercise ; peak o2 per kilogram ;hazard ratio ; peak o2 per kilogram ; PASp
pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; cardioverter-defibrillator device
Rad ; rem ; Rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; regulates ventricular action potential duration ; EC coupling gain ; cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
Swedish web-system for enhancement and development of evidence-based care ; Heart disease ; Recommended Therapies registry ; primary isolated caBG
LVEF ; clinical composite response ; reverse remodeling parameters ; time to death ; HF hospitalization ;hazard ratio
brain natriuretic peptide ; bNP ; bNP ; bNP
coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C ; enrollment ;renal function end point
tpse ;longitudinal RV fiber shortening ; PASp ;force ; RV ; length-force relationship ; disclosing prognosis
pde superfamily ; pde2 ; cgm ; cAMP hydrolysis ; negative cross talk ; cgm ; cAMP signaling
na-terminal probNP ;NT-probNP ; midregional proanp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
re-hospitalization ; admissions
mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ; SS20 ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin
uPR ; sn5a ; ventricular systolic HF tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hipsc-CMs
ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers
cochrane Effective practice ; organisation of care taxonomy
coPD ; CHF ; cRF ; ICC ; kappa coefficients
heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
implantable cardioverter-defibrillator deactivation ; implant ; clinical status ; end-of-life
heart failure ; myocardial function ; dilated ; contracting ventricles
implantable cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
global left ventricular longitudinal systolic strain ; gls ; left ventricular mechanics ; adverse cardiovascular ;CV ; events ; atrial fibrillation ;AF
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
MI ; yielded hazard ratios ; early-onset HF
Medicare ; patients ; acute care hospital ; HF ; AMI ; pna
cardiovascular events ; baseline sst2 status ; BB ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ;AUcs ; NRIs
early-onset ; late-onset HF ; HF ; EF ; HF ; HF ; MI
incubation ; EC ; HDl ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
carvedilol ; von Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
mouse heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
tests-retest reliability ; Timed up & go ; tg ; tests ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
exercise ; intramuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
hospitalized ; HF ; LVEF ; long-term mortality ; LVEF
gls outperformed left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; cv events
heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; ejection fraction ;EF ; HF ; sex
RM ; home telemonitoring ; implanted monitoring devices ; medical support ; ss ; contact ;HH ; human-to-machine interface ;HM
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
ethically ; pediatrics ; families ; religious beliefs ; life-sustaining treatment ; legal majority ; decisions
preferences ; prescribing ; guideline-recommended medications ; medical records
cost ; rhythm-control ; rate-control
median age ; women ; left ventricular ejection fraction ; median egf
fit ; unfit ; cRF distribution ; hazard ratios ; unfit ; overweight ; body mass index ; obese
cRT group ; control group ; hazard ratio ; confidence interval
HFPSI model ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart association ; diabetes status ; atrial fibrillation ;flutter
Medicare Patient Safety monitoring system ;MPSMS ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia
cd34 ; vegf2 ; cells ; functional capacity ; cd34 ; vegf2 ; cells ; peak VO2
practice-level variation ; guideline-recommended treatment ; outpatients ; heart failure ; reduced ejection fraction
case-fatality rate ; concurrent HF ; HF ; case-fatality rate
CHF ; race/ethnicity ; cumulative anthracycline exposure ; stem cell source ;allogeneic ; autologous
tension ; fpassive-sarcomere length relations ; muscle strips ; kcl-KI ; unanchors titin ; titin ; extracellular matrix ; fpassive
reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hsCRp
readmission ; aCR ; potential Preventable Readmission ; pPR ; centers for Medicare ; Medicaid ; cm
congestive heart failure visits ; ED
exercise duration ; rehabilitation ; distance ; walking
arginine vasopressin ; aVP ; physiologic processes ; CHF inhibition ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
sodium-restricted dietary ; stop hypertension ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
rats ; hearts ; excised ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; gln27 ; gly16 ; glu27
acute HF trials ; RELAX-aHF ; ASTronAUT ; PRONTO
hospitalized HF ; international classification of Diseases ; Ninth revision ; Clinical Modification codes ; principal discharge diagnosis
Pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
Rad ; Q65p ; gating movement ; channels ; wild-type Rad ; Q65p ; l-type channel inhibition ; RGK proteins
SS20 ; heart failure ; global proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
discharge ; follow-up visits
heart failure ; end stage ; refractory ; terminal heart failure
heart failure discharges ; university of connecticut health center ; follow-up
New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF
echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; IVc occlusion ; biVP ; twist ; basal rotations ; RS
drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF induced ; mice ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; rate ; postexercise phosphocreatine resynthesis ; Fontan
i-mig ; cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; incidence ; deaths ; heart failure ;HF ; AMI
h-dKO mice ; ventricular mass ; cardiac apoptosis ; fibrosis ; failure ; Akt ; forkhead box ; o-1 signaling ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; left anterior descending ;LAD ; proximal circumflex artery ;LCX ; LCX ; LAD
postmarketing trials ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
cox modeling ; Heart Failure Patient Severity index ;HFPSI ; university of Michigan ; HF ;um
pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; l-type ca2 ; current amplitude ; inotropic effect ; acute β-AR stimulation ; basal contractility
inappropriate ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
joint associations ; cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; hospitalization ; survIval study ; Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ;VVd ; STE ; circumferential strain ;CS ; radial strain ;RS
New York Heart association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
non-LBBB ; QRs ; hazard ratio ; primary outcome
dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC ; heart failure ; signaling pathway
CHF-derived c-K ; cells ; transforming growth factor-β ; tg-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
pKA ; regulatory ;RIiα ; catalytic ; cα ; phosphorylation ; HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; HF
g-protein-coupled receptors ; physiological ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor ; rat model ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
body ; diet group ; exercise group ; exercise ; diet group
risk of event ; RV dysfunction ;hazard ratio ; CI ; cachexia ;hazard ratio
resting HR ; baseline ; VO2max
tg-β inhibition ; c-Kit+ cell ; function ; vitro ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hsCRp ; il6) ; hsCRp ; hsCRp
bets ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; N-terminal pro-brain natriuretic peptide ; heart failure ; GDMT-treated NYHA ; HF
p70s6k ; PKc-βII ; HDl ;NYHA-IIIb ; malondialdehyde bound ; HDl ;NYHA-IIIb ; HDl
MLHF ; exercise ; diet ; exercise
nonpace ; non-DNx ; sham-innervated ; sham-inv ; nonpace DNx ;sham-nx ; pace non-dx ;CHf-inv ; pace ; DNx ;CHf-inv
hABC ; battery score ; HF ; health ABC ; HF model ; SD ; HF ; death ; competing risk
sex ; ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
hemoglobin ; hgb ; HRQoL ; training-induced changes ; HRQoL ; Heart Failure ; controlled Trial Investigating outcomes of exercise training ;HF-ACTION
atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; Québec ; rhythm ; rate-control ; treatment
heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
calcineurin ; nafat signalling ; miR-25 expression ; basic helix-loop-helix ;bhlh ; transcription factor dHAND ; Hand2 ; diseased human ; mouse myocardium
exercise time ; PSSS ; btes ; exercise ; PSSS ; btes
NT-probNP cutoff point ; admission ; pg/ml
prognostic power ; r-r interval oscillations ; non-linear HR variability ; short-term fractal scaling exponent
Diastolic function ; diastolic ; filling formalism ; relaxation ;viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; spontaneous ventricular tachycardia ;HF ; HF ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; adverse CV events
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-d
cost-effectiveness ; heart failure ; management ; evidence-based treatments ; health care system
human resistin ; heart failure ; humanized mouse model ; murine resistin ; transgenic ; human Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin levels
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers
tgtttMena mice ; cardiac injury ; ejection fraction ; fractional ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation for Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; primary end point ; mortality ; heart failure
heart failure ; italy ; confirmatory factor analysis ; cFA ; SCHfi ; self-Care management ; self-Care Confidence
functional status ; mwt ; NYha ; HFpEF ; hFrEF ; adherence ; therapy ; HFpEF ; death ; HF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling ; therapeutic
CHF ; SD testosterone levels ; testosterone
functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; MR ; prolapse ; degenerative mitral valve
New York Heart association ; kccq ; symptom ; Spearman correlations ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
c57b ; ang II infusion ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading ;ANS
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
LV systolic indices ;LV ejection fraction ; LV ; strain rate ; systole ; diastolic indices ; LV ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
peak VO2 ; exercise ; body mass
age ; sex-adjusted risk ; hazard ratios ; early-onset HF ; late-onset HF
AMI ; hospital ; p-value
Mass spectrometry ; N- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis ; pro2- leu3 ; leu3-gly4 ; pro6-gly7 ; pro75-Arg76
ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF prediction model
HFpEF ; New York Heart association ; mean ejection fraction ; fes
depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart Failure ; Reduced ejection Fraction ; clinical trial ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
enrollment period ;hazard ratio ;HR
HF ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; c'd
adjusted hazard ratios ; cRF ; overweight ; obese body mass index
kccq ; HFpEF ;log rank ; EF
baseline egFR group ; egFR group ; egFR group ; uncontrolled hypertension ; diuretics ; ecr
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2 ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
follow-up visits ; death ; urgent readmission
Mena overexpression ; TTA ; tgtttMena mice ; TAC surgery ; Mena levels ; cardiac hypertrophy ; TTA ; tgttttMena ; post-TAC cardiac
echocardiography ; LV ; end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; mean pressure gradient
PD ; diuretic refractory severe-end-stage HF
ATP production rates ; post-aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ;PB
bottleneck stent ; proximal LAD ; LCX ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; non-AAs ; AAs ; race ; treatment
obese participants ; body mass index ; chronic ; stable HFPEF
proangiogenic effects ; b act ; activation ; veGF pathway ; rats ; adenoviral vector ; decoy ; veGF receptor ; ad-flk ; control adenovirus ; ad-c
post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
exercise-induced pulmonary artery ; systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDline ; EMBAse ; HEalthSTAR ; cinahl ; cochrane Library ; Campbell ; Joanna Briggs institute ; evidence based practice ; reviews and Dissemination ; evidence based practice
veterans ; VA health care systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; blockade ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; STE ; change ; RVPO ; RS synchrony ; CS ; biVP ; co
tAPse ; PASp ; tAPse-to-PASp ratio ;TApse ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
cPET ; CHF ; exercise ; exercise
human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac na+ channel α-subunit ; scn5a ; truncated ; nonfunctional channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease
economic analysis ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; evidence-based medications ; costs
natriuretic peptides ;NPs ; b-type NP ; N-terminal pro-B-type NP ; acute heart failure ; Emergency department ;ED ; acute dyspnea
peak oxygen consumption ; peak VO2 ; ven ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
Denmark ; bisphosphonates ; raloxifene ; general population
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; opening ; organic lesion ; systolic ; diastolic tethering ; MR ; MS
tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ;HF
acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure response ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
admission ; lVET ; unfavorable outcome ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure ; reversal of changes ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA level ; β-myosin heavy chain ; metoprolol
HDL ; gh-NYHA-III ;HDl ;NYHA-IIIb ; CHF-NYHA-II ;HDl ;NYHA-II
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular ; end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; md ; relative value ; md ; md
baseline ; heart failure ; t1-mapping ; administration ; contrast agent
etiologies ; HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 levels ; functional capacity ; clinical outcomes ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating outcomes of exercise training ; HF-action ; exercise training ; HF
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHf ; CardioPulmonary exercise testing ; cPET ; exercise rehabilitation ; China
ischemic HF pathogenesis ; NYHA ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-action ; exercise training ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left vEntricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLnKA GG
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated aCF groups ; sham group
e-lateral ; s'lateral ; aUC ; s'lateral ; aUC
spironolactone ; risk of hospitalization ; adjusted hazard ratio
rate-control patients ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs ; cp
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ;EPheSUS ; post-myocardial infarction ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-cRT ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
risk reduction ;HR ; heart failure-related mortality ; sudden death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortality ; hospitalization ; HF ; LVEF ; Heart Failure Survey ; irael
idiopathic dilated cardiomyopathy ; negative coronary angiography
european society of Cardiology ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV ; diastolic stiffness ; elevated LV filling pressures
signaling paradigms ; β1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
pf-cpt ; PAf levels ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ;mean ejection fraction ; standard cardiac rehabilitation ; Nordic walking
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; insulin
skeletal muscle mass ; t-score ; figure ; sarcopenic range ; muscle wasting ; t-score
exercise ; testosterone group ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical outcomes ; short-Form quality of life ; exercise ; placebo group
RAS- ; β-blocker uptitrations ; composite end-point ; all-cause mortality ; HF ; readmissions ; hFref ;hazard ratio ;HR
Heart Failure ; controlled Trial Investigating outcomes of exercise training ;HF-action ; social support ; barriers to exercise ; pss ; barriers to exercise score ; btes
ST2 ; hospitalization ;hazard ratio ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ;hazard ratio ; log2
New York Heart association ; cardiopulmonary exercise testing ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
low-dose dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs duration ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
baseline ; HF ; lyso-paf-AT ; PAf-cpt ; PAf levels ; PAf-AH ; lp-PLA2
medical therapy ; redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
cutoff value ; plasma N-terminal pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; admission ; emergency department ;ED
cardiac troponin t ; ctnt ; high-sensitivity assay ; N-terminal pro-b-type natriuretic peptide ;NT-probNP ; incident HF ; HF risk prediction ; Atherosclerosis risk in communities ;ARIc
body mass index ; event rate ;HR ; fat mass ; fat-free mass index
cod ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis
EH ; LV contractility ; LVEF ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ;β coefficient
echocardiography ; dilated LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; MS ; mVA ; pressure gradient
double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate ; admission
bets ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor ; activated T cells ; naFAT ; nuclear factor-κb ;NF-κb ; transcription factor gATA4
mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality ; hazard ratio
interaction effect ; EO-cfus ; diabetes ; 10-EO-CFU ; peak VO2 ; diabetes ; EO-CFUs ; peak VO2
immunoblotting ; radioenzymatic- and fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; isolated cardiomyocytes ; HF
east ; atrial fibrillation ; Stroke prevention Trial
exercise capacity ; peak oxygen consumption ;VO2 ; co-primary outcome ; Minnesota Living with Heart Failure ;MLHF
TAC-induced proteomic ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; upstream signal ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
low left ventricular ejection fraction ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; financial costs
HF ;HF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; N-terminal pro-brain-type natriuretic peptide
low-volume EDs ; hospitalized ; high-volume EDs
cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
habb ; battery scores ; health ABC ; HF ; risk model ; discrimination ; c-index ; HF
cfi ; RMsea ; self-Care management Scale ; cfi ; RMsea ; self-Care management Scale ; cf ; RMsea ; self-Care Confidence scale
BAT ; quality-of-life score ; NYHA
preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; right ventricular assist devices
SAF ; PF ; PF ; central venous pressure ; gg ; sVR index ; dyn ; cardiac index
admission median ; bNP levels ; EF ; preserved EF ; bNP ; EF ; borderline ; pg/mL
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
LV ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV ; hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt ; ec ;LVh ; rwt
angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; pilot trial ; heart failure ; preserved ejection fraction ; heart failure ; reduced ejection fraction
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory
LVEF ; long-term mortality ; preserved ; LVEF ; age-by-LVEF
wstar-kyoto ; lean zSF1 ; obese zSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
Kaplan-meier curves ; log-rank testing ; UM/VA ;VA-RT cohorts
multivariate cox regression ; AF type ; lack of hypertension ; maintenance ; sinus rhythm ;hazard ratio ; HR
chronic HF-ref ; NYHA ; functional class II ; egf ; potassium ; eplerenone ; hyperkalemia ; wRF
ff ; FM ; body fat distribution ; dual energy x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; non-cachectic CHF ; myocardial infarction-both
baseline ; drug dose ; spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; HF hospitalization ; btes ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
index ED ; low-volume ED cases ; 30-day death ;all-cause readmission ; high-volume EDs
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ;hazard ratio ; pulmonary vascular resistance ; cardiac events
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; laboratory ; echocardiographic ; cardiopulmonary exercise test
end stage heart failure ; ABCd classification ; American college of Cardiology ; acc ;American Heart association ; AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure ; physical exertion ; medical
mVA ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow volume ; mVA ; velocity time ; mitral filling flow ; wave doppler echocardiography ; MR ; mitral valve plasty
statitistical ; RM ; sts ; HH ; crI ; office hours ; t24/7
externally validated ; HFPSI ; Ann arbor Veterans' Affairs ; HF ; hawp ; va-RT cohort ; VA ; HFPSI ; HFPSI
AAs ; non-AAs ; spironolactone dose ; hyperkalemia ;potassium
preserved LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; preserved LVEF
HFpEF ; primary outcome ; wha ; distance ; walk test ; mwt ; adherence ; medications
echo-derived pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; end-systole ; heart failure ;HF ; cardiac risk
severe CAD ; diabetes ; electrocardiographic ; waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco
receiver ; operating characteristic curve ;AUc ; e/e ; ratios ; PCWP ; e/e ;septal ; e/elateral ; e/emean
trastuzumab-treated patients ; coronary artery disease ; gh ; hypertension ; CHF
LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV ; end systolic volume index ; LV mass
tg-β signaling ; tg-β receptor ; smad ; small-molecule inhibitors ; c-Kit ; cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit ; cell differentiation ; cardiomyocyte-like cells
hFrf ; diuretics ; co-morbidities ; distance ; mwt ; NYHA class III
HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mVA ; mean pressure gradient ; fg
systolic heart failure ;ejection fraction ; placebo ; ivabradine ; SHIft ;Systolic Heart Failure Treatment ; if inhibitor ivabradine Trial ; ivabradine ; echocardiographic
Hazard ratios ; tpse ; pasp ;hazard ratio ; tpse ; New York Heart association ; functional class
Renal function ; Chronic Kidney Disease Epidemiology
PARADIGm-HF ; chronic heart failure ; systolic dysfunction ;LV EF ; NYHA II-III ; bNP ; bNP ; primary endpoint ;cardiovascular death ; hospitalization ; heart failure ; arni ; sacubiltril ; valsartan
reverse remodeling ; pre-CRT LV ; end-diastolic dimension ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular fractional area change
hyperkalemia ; African Americans ;AAs ; non-AAs ; New York Heart association ;NYHA ; IV HF ; left ventricular dysfunction ; spironolactone ; aldactone evaluation study ;RALes
iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dKO ; mice
b-type natriuretic peptide ; N-terminal pro-B-type natriuretic peptide ; stable coronary artery disease ; b-type natriuretic peptide ; bNP ; N-terminal fragment ;NT-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers
ivabradine ; treatment ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; exercise capacity ; ivabradine ; peak oxygen uptake
liberal transfusion protocols ; short-term mortality rates ; aggressive protocols ; relative risk ; acute coronary syndrome
risk of death ; unplanned readmission ; physician ; adjusted hazard ratio ;HR ; confidence interval ; CI ; unfamiliar physician ; follow-up
hek ; embryonic kidney ; β1AR ; s1PR1 ; downregulation ; sphingosine-1-phosphate ; s1PR1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
baseline ; walk distance ;Kansas City Cardiomyopathy ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
Odds ratios ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate
in conjunction ; diastolic function ; ea ; ventricular-arterial coupling ; ees
hazard ratios ; disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
revascularization ;coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical treatment ; biomedical treatment ; CHm ; effective rate ; left ventricular ejection fraction ; left ventricular diastolic end diameter
heart failure ; left ventricular ejection fraction ; arg16 ; gln27 ; gly16 ; glu27 haplotype ; β2-receptor ; carvedilol ; metoprolol
low-volume ED cases ; death ;hospitalization ;ED
health Buddy program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ; CI ; inpatient admissions ; baseline ; matched controls
multivariable-adjusted hazard ratios ; DASh ; diet score
ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ;AUC ; discrimination ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; egf ; serum potassium
low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; placebo ; cystatin c level ;nesiritide ; placebo
standard care ; Nordic walking led ; functional capacity ; self-reported physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety and depression Scale
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; cdp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ; pf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; serum ; leukocytes
ivabradine group ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
CHF ;Odds Ratio ; pre-HCT ; chest radiation ; hypertension ; genes coding ; NAD(ph-oxidase ; RAC2 ; hfe ; doxorubicin efflux transporter ; abc2
baseline ; baseline ; NYHA classification ; class III ; class III ; change ; Duke activity status index ; Kansas City Cardiomyopathy ; walk test distance
placebo ; low-dose dopamine ; 72-hour cumulative urine volume ;dopamine ; placebo ; cystatin c level ; dopamine ; placebo ; cystatin c level
figure ;hazard ratio ; baseline glomerular filtration rate ; baseline glomerular filtration rate ; diabetes ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; change of diet in renal disease ; sodium
Kansas City ; cardiomyopathy ; Minnesota ; Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; placebo ; natriuretic peptide ; mitral e/e ; wave ratio
